# US 2026/0034159 A1 · Methods for producing cyclic dinucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0034159 A1
- Document ID: US20260034159A1
- Status: Published application
- Kind: A1
- Application number: 19/099,727
- Filed: 2023-08-10
- Published: 2026-02-05
- Earliest claimed: 2022-08-10
- Assignees: Aldevron, LLC
- Applicants: Aldevron, LLC
- Inventors: DENIS ARUTYUNOV; TODD MICHAEL VANNELLI
- Web page: https://patentgrep.com/patent/US20260034159A1

## CPC

- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- C12N 1/02: Separating microorganisms from their culture media
- C12N 1/06: Lysis of microorganisms
- C12N 1/20: Bacteria; Culture media therefor
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 15/1017: {by filtration, e.g. using filters, frits, membranes}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12P 19/36: Dinucleotides, e.g. nicotineamide-adenine dinucleotide phosphate
- C12Y 207/07: Nucleotidyltransferases (2.7.7)
- C07K 2319/00: Fusion polypeptide
- C12R 2001/19: Escherichia coli
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure provides a method of producing cyclic dinucleotides (CDNs) on a commercial scale. Also provided are pharmaceutical compositions comprising a purified CDN preparation and use thereof to stimulate the immune system in a subject.

## Claims

### Claim 1

A method of producing cyclic dinucleotides (CDNs), comprising: (a) incubating CDN-producing recombinant E. coli cells in a culture medium in a fermenter to produce a desired amount of CDN; (b) removing the cells from the cell culture medium to obtain a cell-free culture medium containing CDN; (c) filtering the cell-free culture medium to remove cell debris; (d) reducing the salt concentration of the filtered culture medium through dilution; (e) isolating CDN from the mixture of step (d) through a column that does not comprise affinity binding; and (f) purifying the isolated CDN through nanofiltration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the recombinant E. coli cells are incubated in a minimal fermentation medium in the fermenter, optionally wherein the minimal fermentation medium is supplemented.

### Claim 3 (depends on 2)

The method of claim 2, wherein the supplemented minimal fermentation medium comprises: M9 minimal salts; 0.8-3% glucose; 5-10 mM MgSO 4; 0.1-0.3 mM CaCl 2; and 0.01-0.03 mM ferrous sulfate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the recombinant E. coli cells comprise a codon-optimized version of a mouse cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (mcGAS) gene.

### Claim 5 (depends on 1)

The method of claim 1, wherein the recombinant E. coli cells contain (i) extra copies of one or more of E. coli argU, ileY, leuW, and proL tRNA genes; and/or (ii) a plasmid bearing a constitutively active lacI repressor gene.

### Claim 6 (depends on 4)

The method of claim 4, wherein the mcGAS gene is expressed in the recombinant E. coli cells as part of a small ubiquitin-like modifier (SUMO) fusion protein.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the fermenter has a culture volume of 1 L to 1000 L.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein between steps (d) and (e) the method comprises subjecting the diluted mixture through weak anion-exchange resin or molecular weight cut-off (MWCO) filtration to remove impurities.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein step (e) comprises: contacting the diluted mixture containing CDN with a solid support comprising strong anion-exchange resin, wherein CDN in the mixture binds to the solid support; washing the solid support with a washing buffer to remove biological materials other than bound CDN, and preferentially eluting the bound CDN from the solid support with an elution buffer to obtain a substantially pure CDN preparation.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the washing buffer is a neutral buffer, optionally comprising 20 mM Tris-HCl, pH 7.2.

### Claim 17 (depends on 14)

The method of claim 14, wherein the elution buffer comprises 20 mM Tris-HCl, pH 7.2, and 100-200 mM NaCl.

### Claim 18 (depends on 14)

The method claim 14, wherein the CDN preparation is further filtered to remove endotoxin.

### Claim 19 (depends on 1)

The method of claim 1, wherein step (f) comprises concentrating the CDN using tangential flow nanofiltration or direct flow nanofiltration.

### Claim 20 (depends on 1)

The method of claim 1, wherein the CDN is 2′,3′-cGAMP; c-di-GMP; or 3′,3′-cGAMP.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a purified CDN obtained by the method of claim 1.

### Claim 22 (depends on 21)

A method of stimulating the immune system in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 21.

### Claim at position 23

-25. (canceled)
